June 22, 2023 News by Marisa Wexler, MS Pregnancy hormone estriol promotes myelin repair in MS mice Treatment with estriol, a hormone that’s produced during pregnancy, reduced disease severity and promoted myelin repair in the cortex ā a key brain region affected in multiple sclerosis (MS) ā in a mouse model of the disease. Those are the main findings of the study, āNeuroprotection in cerebral…
July 11, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: COVID-19, Predicting Progression, Early Treatment, Estriol Higher COVID-19 Risk Tied to 2 MS Therapies, Even With Vaccination According to this study, people being treated with Ocrevus had 3.6 times the risk of a breakthrough COVID-19 infection compared with people being treated with most other disease-modifying therapies. For those treated with Gilenya, the risk was increased…
July 5, 2022 News by Steve Bryson, PhD Estriol Plus Copaxone May Protect Against Nerve Damage in RRMS Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) ā a marker of nerve damage ā in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…
November 16, 2017 News by Patricia Silva, PhD Studies of Sex Differences in MS Led Researcher to Pregnancy Hormone as Potential Treatment A pregnancy hormone called estriol may be effective in controlling relapses in women with multiple sclerosis (MS), says a researcher at the University of California, Los Angeles (UCLA). In clinical trials, estriol has also lowered fatigue and improved thinking ā work that originated in Rhonda Voskuhl’s quest to understand…
June 8, 2017 Columns by Tamara Sellman The MS Alphabet: EVP, Exacerbations, Estriol and more ‘E’ words (Editorās note: Tamara Sellman continues her occasional series on the MS alphabet with this first of two parts on terms starting with the letter āE.ā) When it comes to multiple sclerosis, mastering an understanding of the disease means you need to mind your Ps and…
February 8, 2016 News by Margarida Azevedo, MSc Experimental RRMS Therapy, Trimesta, Fails to Demonstrate Efficacy in Review of Clinical Trial Synthetic Biologics, Inc., a clinical stage company focused on the development of therapeutics to protect the microbiome and to target disease-causing pathogens, recently announced disappointing results from an independent third-party analysis of a Phase 2 clinical trial evaluating Trimesta as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women.
December 2, 2015 News by Patricia Silva, PhD Experimental Relapsing-Remitting MS Drug Treatment Advancing Synthetic Biologics, which specializes in the development of therapies forĀ pathogen-specific diseases, recently announced theĀ publication of new and positive data on results from a Phase 2 clinical trial evaluating the companyās product Trimestaā¢ as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women. Professor Rhonda Voskuhl, director of theĀ Multiple Sclerosis Program…
August 1, 2014 News by admin Data From Multiple Sclerosis Study of Trimesta For Disability, Cognitive Improvements in Women To Be Presented at ACTRIMS-ECTRIMS 2014 Synthetic Biologics, Inc., a biotechnology company developing novel drug candidates targeting specific pathogens that cause serious infections and diseases, announced that its latest data on Trimestaā¢, regarding cognitive and disability measures in women suffering from multiple sclerosis (MS), will be presented at the 2014 Joint Americas and European Committees…
May 20, 2014 by Patricia Silva, PhD Combination Therapy For Multiple Sclerosis Offers Promising Results In Recent Study Positive study results from a preliminary phase II clinical trialĀ for a new potential therapeutic intervention for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) were recentlyĀ released at the American Academy of Neurology’s Annual Meeting in Philadelphia by Dr.Ā Rhonda Voskuhl, M.D., from the University of California, Los Angeles.